This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

9-Methyl-β-carboline

Well Researched

Polanski lab's 2007-2020 preclinical work (rat + primary cell culture) shows 9-Me-BC does an unusually long list of useful things to the…

Aliases (7)
9-Me-BC · 9-MBC · 9-methyl-beta-carboline · 9-methyl-9H-pyrido[3 · 4-b]indole · 9-methyl-norharman · CAS 2521-07-5
TYPICAL DOSE
5 mg/day
Daily
ROUTE
Oral (tablet)
Oral
CYCLE
2 weeks on / 2 weeks off
As prescribed
STORAGE
Room temp; original container
Room temp

Overview

What is 9-Methyl-β-carboline?

9-Methyl-beta-carboline (9-Me-BC) is a beta-carboline alkaloid, naturally trace-present in roasted coffee and certain plants. It is investigational and is used in the nootropic community for sustained dopaminergic and pro-cognitive effects without classical stimulant feel.

Key Benefits

Reported sustained cognitive enhancement, motivation, and dopaminergic tone; preclinical work shows neuroprotection of dopaminergic neurons and increased dendritic complexity. Anecdotally cumulative — effects build over days to weeks.

Mechanism of Action

Reversible MAO-A inhibitor, mild dopamine reuptake inhibitor, and inducer of neurotrophic factors (BDNF, GDNF). Shows neuroprotective action on dopaminergic neurons and increases dendritic arborization in preclinical models.

Pharmacokinetics

·
PeakHalf-life
Approximate curve — visual aid only, not data-precise PK
Brand options1 known
CAS 2521-07-5

StatusUnscheduled in US; not FDA-approved for any indication; research-chemical-only — sold by research-chem vendors with "not for human consumption" labeling

Research Indications

Most Effective

What β-carbolines are (and why "9-methyl" matters)

β-carbolines are tricyclic pyridoindole alkaloids found endogenously in human brain and many plants (Banisteriopsis caapi / ayahuasca's h…

Effective

The five-arm mechanism (preclinical)

1. Tyrosine hydroxylase (TH) upregulation in dopaminergic neurons. TH is the rate-limiting enzyme in dopamine synthesis (tyrosine → L-DOP…

Investigational

Pharmacokinetics — the empty box

Almost no human PK data exists. The Polanski-lab work is animal-only. From the limited animal + biohacker-inferred data: - Half-life: Est…

Peptide Interactions

Bromantane:
Synergistic

Mechanistically complementary — bromantane upregulates TH via cAMP/PKC + CpG demethylation; 9-Me-BC upregulates TH via PI3K/Akt + transcription-factor (Gata2…

NSI-189:
Synergistic

Both hippocampal neurogenesis-tropic, different molecular routes (NSI-189: BDNF + GDNF + VEGF + SCF; 9-Me-BC: BDNF + artemin + NT-3 via astrocyte recruitment…

Cerebrolysin:
Synergistic

Could plausibly combine — cerebrolysin delivers neurotrophic peptide fragments parenterally; 9-Me-BC induces endogenous neurotrophic factor expression. Diffe…

Apigenin:
Synergistic

Apigenin is a MAO-A/B inhibitor in vitro at high doses; combination would likely be additive rather than synergistic. Avoid stacking at high doses of either.

Selegiline:
Avoid

MAO-overlap concern. Selegiline at 1-2.5 mg oral is MAO-B-selective (~90% selectivity); 9-Me-BC inhibits both MAO-A (preferentially) and MAO-B. Stacking adds…

Other MAOIs (rasagiline, moclobemide, tranylcypromine, phenelzine, isocarboxazid):
Avoid

Same logic — additive MAO inhibition. Avoid.

SSRIs / SNRIs / TCAs / tramadol / MDMA / high-dose DXM / St. John's Wort:
Avoid

Theoretical serotonin-syndrome risk via MAO-A inhibition arm. Avoid.

Other β-carbolines (harmine, harmaline, ayahuasca, Syrian rue extract):
Avoid

Additive MAO inhibition + DNA-photosensitization risk. Avoid.

Stimulants at high dose (amphetamine-class):
Avoid

MAO-A inhibition will potentiate amphetamine-induced monoamine release — hypertensive risk. Modafinil is theoretically lower-risk (no monoamine-release mecha…

Levodopa:
Avoid

Theoretical risk of excessive peripheral catecholamine accumulation. Avoid.

Quality Indicators

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed packaging from a licensed pharmacy.

!

Generic vs branded

Generics are usually fine but bioavailability can vary slightly; track if you switch.

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

  • Day 1
    PK-driven acute peak per administration. Verify dose tolerated.
  • Week 1
    Steady-state reached for most daily-dosed pharma.
  • Week 2-4
    Therapeutic effect established; titration window if needed.
  • Long-term
    Periodic monitoring per drug class (labs, BP, ECG as applicable).

Side Effects & Safety 8

Side Effects

  1. 1Headache (early dosing, often resolves)
  2. 2GI upset / nausea
  3. 3Sublingual taste loss (sublingual route only — persistent, can last 1-2 weeks)
  4. 4Photosensitivity (skin reaction on UV exposure — see watch period)
  5. 5Mild anxiety / edge (especially >15-20 mg)
  6. 6Dizziness, flushing
  7. 7Increased dream vividness (MAO-A inhibition extending monoamine half-life)
  8. 8Mood disturbance (reports of irritability or aggression at higher doses)

When to Stop

  • UVA-induced DNA damage — Wenz et al. 2013 (RSC Org Biomol Chem, "Mechanisms of DNA damage by photoexcited 9-methyl-β-carbolines") demonstrated that 9-methyl-β-carbolines under UVA irradiation in cellular assays produce 8-oxo-7,8-dihydroguanine (a mutagenic oxidized purine), single-strand DNA breaks, abasic sites, micronucleus formation, and decreased cell proliferation. The DNA damage pattern is type-I photochemical (radical-mediated) and predominantly oxidized-purine-skewed. Translation to whole-organism cancer risk in chronic biohacker users is unquantified — the effect is documented in cell models, has not been studied in human skin in vivo, but the mechanism is concerning enough that "stay out of strong sun while dosing and for 3-7 days after stopping" is the consensus biohacker recommendation. For a combat athlete with outdoor training exposure, this is non-trivial.
  • Tyramine pressor reaction (theoretical, MAO-A inhibition mechanism) — IC50 1 μM for MAO-A means at sufficient plasma concentration the molecule could behave like a partial MAO-A inhibitor. Tyramine-rich foods (aged cheese, fermented soy, tap beer, cured meat) could in principle produce hypertensive reactions. No documented human cases, but the mechanism warrants dietary awareness on chronic dosing.
  • Serotonin syndrome (theoretical) — combining 9-Me-BC with serotonergic drugs (SSRIs, SNRIs, tramadol, MDMA, high-dose DXM, St. John's Wort) is theoretically dangerous. No documented human cases, but the MAO-A inhibition arm makes the textbook risk real.
  • α-synuclein/dopaminergic effects in chronic high-dose use — the Parkinson's-relevant dimethyl-β-carboline congeners are dopaminergic neurotoxins. 9-methyl appears protective in the published literature, but very-long-term effects in humans are entirely uncharacterized.
  • Hepatic effects (theoretical) — β-carboline class includes some hepatotoxic compounds; 9-Me-BC liver-toxicity profile in humans is uncharacterized. ALT/AST monitoring at 4-week intervals if cycling repeatedly is prudent.
  • Photosensitivity: entire dosing period + 3-7 days post-discontinuation. Avoid prolonged direct UV exposure. SPF 50+ on uncovered skin if outdoor exposure unavoidable. This is the most concrete and most-commonly-violated safety guidance.
  • First 2 weeks: monitor mood (anxiety/aggression flag), GI tolerance, photosensitivity reaction.
  • Month 1+ chronic use: ALT/AST, BP, mood-self-report.

References

Wikipedia: 9-Methyl-β-carboline

en.wikipedia.org

chemistry, dosing range, mechanism summary, photosensitivity note

View Study

Keller et al. 2020, J Neural Transm (PMC8592951)

pmc.ncbi.nlm.nih.gov · 2020

MAO IC50 values (MAO-A 1 μM, MAO-B 15.5 μM); BDNF + artemin + NT-3 + NCAM1 + TGF-β2 fold-changes in astrocytes; PI3K/Akt pathway dependence

View Study

Polanski et al. 2010, J Neurochem (PMID 20374418)

pubmed.ncbi.nlm.nih.gov · 2010

"The exceptional properties of 9-methyl-β-carboline" — dopaminergic neuron stimulation/protection/regeneration + anti-inflammatory mechanism review-primary

View Study

Hamann/Wagner/Polanski 2008, Neurotoxicology (PMID 17913302)

pubmed.ncbi.nlm.nih.gov · 2008

foundational TH upregulation paper in primary mesencephalic culture; 33% TH+ neuron increase peak at 90 μM

View Study

Gruss et al. 2012, J Neurochem (PMID 22380576)

pubmed.ncbi.nlm.nih.gov · 2012

rat hippocampal dopamine + dendritic + synaptic + spatial-learning behavioral effects

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources